Raymond James Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $14
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsInitiationPrice Target
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.
Raymond James analyst Tiago Fauth initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $14.